HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Aurobindo Pharma Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: Jun 05, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1159 as of 05 Jun 15:30.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Mar '25 is ₹ 8516 crore as compare to the Dec '24 revenue of ₹ 8137 crore. This represent the growth of 4.66% The revenue of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 9056 crore as compare to the Dec '24 revenue of ₹ 8535 crore. This represent the growth of 6.1%.
  • The ebitda of Aurobindo Pharma Ltd for the Mar '25 is ₹ 1894 crore as compare to the Dec '24 ebitda of ₹ 1736 crore. This represent the growth of 9.08% The ebitda of Dr Reddys Laboratories Ltd for the Mar '25 is ₹ 2525 crore as compare to the Dec '24 ebitda of ₹ 2427 crore. This represent the growth of 4.04%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 902.83 crore over 8 quarters. This represents a CAGR of 25.89% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1586 crore over 8 quarters. This represents a CAGR of 6.27% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma arm incorporates WOS in Netherlands

The purpose of the incorporation of this wholly owned subsidiary is to expand the biopharm...

Read more

29 May 2025 08:40

News

Aurobindo Pharma announces board meeting date

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 26 May 20...

Read more

17 May 2025 16:08

News

Aurobindo Pharma Ltd Slips 3.92%, BSE Healthcare index Shed 1.06%

Aurobindo Pharma Ltd fell 3.92% today to trade at Rs 1194. The BSE Healthcare index is dow...

Read more

06 May 2025 09:30

News

Aurobindo Pharma drops after fire incident at Kakinada facility

The incident, which occurred on 27 April 2025, has prompted a temporary suspension of oper...

Read more

29 Apr 2025 16:22

News

CuraTeQ Biologics s.r.o. receives positive opinion for biosimilar Dazublys' from EMA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, announc...

Read more

26 Apr 2025 13:58

News

Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets

The drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD...

Read more

23 Apr 2025 12:05

Dr Reddys Laboratories Ltd News Hub

News

Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manu...

Read more

05 Jun 2025 09:20

News

Dr Reddys Lab gains on global biosimilar deal with Alvotech

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $...

Read more

05 Jun 2025 10:10

News

Dr Reddys Laboratories allots 57,840 equity shares under ESOS

Dr Reddys Laboratories has allotted 57,840 equity shares of Re.1/- each of the Company, fu...

Read more

03 Jun 2025 16:28

News

Dr Reddys Labs' manufacturing facility gets two form 483 observations from US FDA

In a regulatory filing made on Saturday (24 May 2025), the company informed that the US FD...

Read more

26 May 2025 09:33

News

DRL's USA facility gets 2 observations from USFDA

The USFDA completed aforementioned inspection and issued form-483 with two observations. H...

Read more

19 May 2025 08:32

News

USFDA completes GMP inspection of Dr Reddy's Middleburgh facility in New York

Dr Reddys Laboratories announced that the United States Food & Drug Administration (USFDA)...

Read more

17 May 2025 11:32

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Dr Reddys Laboratories Ltd?

Market cap of Aurobindo Pharma Ltd is 67,939 Cr while Market cap of Dr Reddys Laboratories Ltd is 107,636 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd?

As of June 5, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1159.5. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1289.9.

How do dividend payouts of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions